Merck, Inc.
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT06179407
- Locations
- 🇺🇸
Delta Waves, Inc. ( Site 0008), Colorado Springs, Colorado, United States
🇺🇸Teradan Clinical Trials, LLC ( Site 0005), Brandon, Florida, United States
🇺🇸NeuroTrials Research Inc ( Site 0006), Atlanta, Georgia, United States
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 820
- Registration Number
- NCT06177912
- Locations
- 🇨🇦
Premier Clinical Trial Network ( Site 0008), Hamilton, Ontario, Canada
🇺🇸Central Research Associates ( Site 0145), Birmingham, Alabama, United States
🇺🇸Velocity Clinical Research, Phoenix ( Site 0122), Phoenix, Arizona, United States
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 614
- Registration Number
- NCT06170788
- Locations
- 🇲🇽
Higiea Oncologia ( Site 0721), Mexico City, Distrito Federal, Mexico
🇲🇽Centro de Atención e Investigación Cardiovascular del Potosí ( Site 0713), San Luis Potosí, San Luis Potosi, Mexico
🇲🇽Clinica Integral Internacional de Oncología ( Site 0714), Puebla, Mexico
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 270
- Registration Number
- NCT06161116
- Locations
- 🇨🇳
Anhui Provincial Hospital ( Site 2043), Hefei, Anhui, China
🇺🇸Medvin Clinical Research - Metyas ( Site 0128), Covina, California, United States
🇺🇸Arthritis & Osteoporosis Medical Center - La Palma ( Site 0108), La Palma, California, United States
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06136598
- Locations
- 🇨🇳
Peking University First Hospital-Urology ( Site 0001), Beijing, Beijing, China
🇨🇳Tongji Hospital Tongji Medical,Science & Technology ( Site 0002), Wuhan, Hubei, China
🇨🇳Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003), Guangzhou, Guangdong, China
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT06136559
- Locations
- 🇨🇿
Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Czechia
🇲🇾Queen Elizabeth Hospital ( Site 1603), Kota Kinabalu, Sabah, Malaysia
🇲🇽Centro de Infusion Superare ( Site 2602), Ciudad de México, Distrito Federal, Mexico
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT06136624
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0036), Palo Alto, California, United States
🇳🇱Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, Noord-Holland, Netherlands
🇵🇱Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, Zachodniopomorskie, Poland
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT06136650
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0036), Palo Alto, California, United States
🇸🇬National University Hospital ( Site 1201), Singapore, Central Singapore, Singapore
🇹🇭Chulalongkorn University ( Site 1355), Bangkok, Krung Thep Maha Nakhon, Thailand
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 710
- Registration Number
- NCT06132958
- Locations
- 🇺🇸
Arizona Oncology Associates - HOPE ( Site 8002), Tucson, Arizona, United States
🇨🇿Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1705), Praha, Praha 2, Czechia
🇺🇸USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama, United States
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
- Conditions
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 165
- Registration Number
- NCT06113328
- Locations
- 🇺🇸
The Vitiligo & Pigmentation Institute of Southern California ( Site 0115), Los Angeles, California, United States
🇹🇷Ankara Bilkent Şehir Hastanesi-Dermatology ( Site 1502), Ankara, Turkey
🇺🇸Cahaba Dermatology & Skin Health Center ( Site 0127), Birmingham, Alabama, United States